Clinical Trial Update: Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating axitinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma has been completed. Results were posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma

Drugs mentioned

• Inlyta (Axitinib) (Axitinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Adenoid Cystic Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-11-28